Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Separation or purification
Reexamination Certificate
2010-04-28
2011-11-29
Saidha, Tekchand (Department: 1652)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Separation or purification
C435S189000, C435S190000, C435S191000
Reexamination Certificate
active
08067553
ABSTRACT:
A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.
REFERENCES:
patent: 3616231 (1971-10-01), Bergmeyer et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4460683 (1984-07-01), Gloger et al.
patent: 4766106 (1988-08-01), Katre et al.
patent: 4847079 (1989-07-01), Kwan
patent: 4847325 (1989-07-01), Shadle et al.
patent: 4917888 (1990-04-01), Katre et al.
patent: 5122614 (1992-06-01), Zalipsky
patent: 5283317 (1994-02-01), Saifer et al.
patent: 5286637 (1994-02-01), Veronese et al.
patent: 5428128 (1995-06-01), Mensi-Fattohi et al.
patent: 5458135 (1995-10-01), Patton et al.
patent: 5468478 (1995-11-01), Saifer et al.
patent: 5541098 (1996-07-01), Caput et al.
patent: 5612460 (1997-03-01), Zalipsky
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5653974 (1997-08-01), Hung et al.
patent: 5711944 (1998-01-01), Gilbert et al.
patent: 5762923 (1998-06-01), Gross et al.
patent: 5811096 (1998-09-01), Aleman et al.
patent: 5824784 (1998-10-01), Kinstler et al.
patent: 5880255 (1999-03-01), Delgado et al.
patent: 5919455 (1999-07-01), Greenwald et al.
patent: 5932462 (1999-08-01), Harris et al.
patent: 5955336 (1999-09-01), Shigyo et al.
patent: 6201110 (2001-03-01), Olsen et al.
patent: 6576235 (2003-06-01), Williams et al.
patent: 6783965 (2004-08-01), Sherman et al.
patent: 6913915 (2005-07-01), Ensor et al.
patent: 7723089 (2010-05-01), Williams et al.
patent: 2002/0010319 (2002-01-01), Ansaldi et al.
patent: 2003/0166249 (2003-09-01), Williams et al.
patent: 2005/0014240 (2005-01-01), Sherman et al.
patent: 2008/0031864 (2008-02-01), Williams et al.
patent: 2008/0057048 (2008-03-01), Sherman et al.
patent: 2010/0323423 (2010-12-01), Williams et al.
patent: 279 486 (1990-06-01), None
patent: 0 043 980 (1982-01-01), None
patent: 55-99189 (1980-07-01), None
patent: 55-135590 (1980-10-01), None
patent: 57-192435 (1982-11-01), None
patent: 62-55079 (1987-03-01), None
patent: 03-148298 (1991-06-01), None
patent: 09-154581 (1997-06-01), None
patent: WO 87/00056 (1987-01-01), None
patent: WO 92/16221 (1992-10-01), None
patent: WO 94/19007 (1994-09-01), None
patent: WO 94/23740 (1994-10-01), None
patent: WO 98/31383 (1998-07-01), None
patent: WO 00/07629 (2000-02-01), None
patent: WO 00/08196 (2000-02-01), None
patent: WO 01/59078 (2001-08-01), None
Osman et al. [Comp. Biochem. Physiol. vol. 94B, No. 3, pp. 469-474 (1989)].
Kunitani et al. [Journal of Pharmaceutical and Biomedical Analysis, vol. 16, pp. 573-586 (1997)].
Abuchowski, A., et al., “Effect of Covalent Attachment of Polyethylene Glycol on Immunogenicity and Circulating Life of Bovine Liver Catalase,”J. Biol. Chem. 252:3582-3586, American Society for Biochemistry and Molecular Biology, United States (1977).
Abuchowski, A., et al., “Reduction of Plasma Urate Levels in the Cockerel with Polyethylene Glycol-Uricase,”J. Pharmacol. Exp. Ther. 219: 352-354, The American Society for Pharmacology and Experimental Therapeutics, United States (1981).
Alvares, K., et al., “Rat urate oxidase produced by recombinant baculovirus expression: formation of peroxisome crystalloid core-like structures,”Proc. Natl. Acad. Sci. USA 89: 4908-4912, National Academy of Sciences, United States (1992).
Alvares, K., et al., “The Nucleotide Sequence of a Full Length cDNA Clone Encoding Rat Liver Urate Oxidase,”Biochem. Biophys. Res. Commun. 158:991-995, Academic Press, Inc., United States (1989).
Bossavy, J., et al., “Comparison of the Antithrombotic Effect of PEG-Hirudin and Heparin in a Human Ex Vivo Model of Arterial Thrombosis,”Arterioscler. Thromb. Vasc. Biol. 19:1348-1353, American Heart Association, United States (May 1999).
Braun, A. and J. Alsenz, “Development and Use of Enzyme-Linked Immunosorbent Assays (ELISA) for the Detection of Protein Aggregates in Interferon-Alpha (IFN-α) Formulations,”Pharm. Res. 14:1394-1400, Plenum Publishing Corporation, United States (Oct. 1997).
Braun, A., et al., “Protein Aggregates Seem to Play a Key Role Among the Parameters Influencing the Antigenicity of Interferon Alpha(IFN-α) in Normal and Transgenic Mice,”Pharm. Res. 14:1472-1478, Plenum Publishing Corporation, United States (Oct. 1997).
Burnham, N., “Polymers for delivering peptides and proteins,”Am. J. Hosp. Pharm. 51: 210-218, American Society of Hospital Pharmacists, Inc., United States (1994).
Caliceti, P., et al., “Biopharmaceutical properties of uricase conjugated to neutral and amphiphilic polymer,”Bioconjugate Chem. 10:638-646, American Chemical Society, United States (Jun. 1999).
Chen, R., et al., “Properties of Two Urate Oxidases Modified by the Covalent Attachment of Poly(Ethylene Glycol),”Biochim. Biophys. Acta 660:293-298, Elsevier/North Holland Biomedical Press, Netherlands (1981).
Chua, C., et al., “Use of Polyethylene Glycol-Modified Uricase (PEG-Uricase) to Treat Hyperuricemia in a Patient with Non-Hodgkin Lymphoma,”Ann. Intern. Med. 109:114-117, American College of Phsycians, United States (1988).
Clark, R., et al., “Long-acting Growth Hormone Produced by Conjugation with Polyethylene Glycol,”J. Biol. Chem. 271:21969-21977, The American Society of Biochemistry and Molecular Biology, Inc., United States (1996).
Colloc'h, N., et al., “Crystal Structure of the protein drug urate oxidase-inhibitor complex at 2.05 Å resolution,”Nature Struct. Biol. 4:947-952, Nature Publishing Group, United Kingdom (Nov. 1997).
Conley, T. and D. Priest, “Thermodynamics and Stoichceiometry of the Binding of Substrate Analogues to Uricase,”Biochem. J. 187:727-732, The Biochemical Society, United Kingdom (1980).
Davis, F., et al., “Enzyme-Polyethylene Glycol Adducts: Modified Enzymes with Unique Properties,” inEnzyme Engineering, vol. 4, Braun, G., et al., eds, Plenum Press, New York, pp. 169-173 (1978).
Davis, S., et al., “Hypouricaemic Effect of Polyethyleneglycol Modified Urate Oxidase,”Lancet 2:281-283, Lancet Publishing Group, United States (1981).
Donadio, D., et al., “Manifestation de type anaphylactique après injection intra-veineuse d'urate-oxydase chez un enfant asthmatique atteint de leucémie aiguë,”La Nouv. Presse Med. 10:711-712, Masson, France (1981) (with English language translation).
Fam, A., “Strategies and Controversies in the Treatment of Gout and Hyperuricaemia,”Ballière's Clinical Rheumatology 4:177-192, Elsevier, Ltd., United Kingdom (1990).
Francis, G., et al., “PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques,”Int. J. Hematol. 68:1-18, Elsevier Science Ireland Ltd., Ireland (Jul. 1998).
Fridovich, I., “The Competitive Inhibition of Uricase by Oxonate and by Related Derivatives of s-Triazines,”J. Biol. Chem. 240:2491-2494, American Society for Biochemistry and Molecular Biology, United States (1965).
Fuertges, F. and A. Abuchowski, “The Clinical Efficacy of Poly(Ethylene Glycol)-Modified Proteins,”J. Control Release 11: 139-148, Elsevier Science, Netherlands (1990).
Fujita, T., et al., “Tissue Distribtuion of111In-Labeled Uricase Conjugated with Charged Dextrans and Polyethylene Glycol,”J. Pharmacobio-Dyn. 14:623-629, Pharmaceutical Society of Japan, Japan (1991).
Gaertner, H. and R. Offord, “Site-Specific Attachment of Functionalized Poly(ethylene glycol) to the Amino Terminus of Proteins,”Bioconjugate Chem. 7:38-44, American Chemical Society, United States (1996).
Greenberg, M. and M. H
Hershfield Michael S.
Kelly Susan J.
Saifer Mark G. P.
Sherman Merry R.
Williams L. David
Duke University
Mountain View Pharmaceuticals, Inc.
Saidha Tekchand
Sterne Kessler Goldstein & Fox PLLC
LandOfFree
PEG-urate oxidase conjugates and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PEG-urate oxidase conjugates and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PEG-urate oxidase conjugates and use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4264687